The Lifeline

Will you join our community of monthly donors and help us save lives through cardiovascular research all year long?

Why Give Monthly?

When you give monthly, you provide a steady and invaluable stream of funding that we can count on. This enables us to dream bigger, set bolder goals, and drive more innovative cardiovascular research and education that saves lives. 

With your continued support, Minneapolis Heart Institute Foundation research physicians are empowered to investigate more questions throughout the year that improve the understanding of cardiovascular disease prevention, diagnosis, and treatment.

In a world that can be unpredictable, you can provide a constant source of hope to brighten the future for patients everywhere.

The Benefits of a Monthly Gift

  • Easiest way to make an impact all year-long.
  • Convenient one-time set-up of monthly payment that can be changed or cancelled at any time.
  • Contribute to the longevity of MHIF’s mission—your gift gets put to work immediately.
  • An eco-friendly and cost-effective giving option: more money goes directly to our work, reducing paper and postal costs.
  • Be part of a community that receives unique insight into long-term impact of your gifts.

Join The Lifeline

Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approval of the TriClip™

blue background

A new treatment for leaky tricuspid valves has been approved by the FDA. This new therapy is available for patients living with the debilitating effects of tricuspid regurgitation. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial – and going back to the first patient to have access to this technology through research.